Literature DB >> 1487399

Binding of a new vinca alkaloid derivative, S12363, to human plasma proteins and platelets. Usefulness of an erythrocyte partitioning technique.

S Urien1, G Bastian, C Lucas, J P Bizzari, J P Tillement.   

Abstract

The interactions of S12363 with human plasma proteins have been investigated in vitro by an erythrocyte partitioning technique that allows a quantitative estimation of the plasma and erythrocytes binding. S12363 was 85-95% plasma-bound and 97-98% blood-bound. The main binding protein in plasma was alpha-acid glycoprotein, with a binding constant of 0.6 x 10(6) M-1, accounting for 70% of total S12363 in plasma. Owing to extensive binding to platelets (40-50% of total blood amount), S12363 was mainly distributed in the non plasma blood compartment, with blood-to-plasma concentrations ratio of 1.2-1.4. These results indicate that, in vivo, the fraction of blood S12363 available for tissue diffusion, i.e., the free drug fraction in blood, should depend on both alpha 1-acid glycoprotein concentration in plasma and blood platelet count.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1487399     DOI: 10.1007/bf00944179

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  12 in total

1.  Binding of retelliptine, a new antitumoral agent, to serum proteins and erythrocytes.

Authors:  C Maulard; S Urien; G Bastian; J P Tillement
Journal:  Biochem Pharmacol       Date:  1990-08-15       Impact factor: 5.858

2.  Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice.

Authors:  M Masquelier; S Vitols; C Peterson
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

3.  Interaction of vinblastine, vincristine and colchicine with serum proteins.

Authors:  D W Donigian; R J Owellen
Journal:  Biochem Pharmacol       Date:  1973-09-01       Impact factor: 5.858

4.  Differences between vinblastine and vincristine in distribution in the blood of rats and binding by platelets and malignant cells.

Authors:  P W Gout; L L Wijcik; C T Beer
Journal:  Eur J Cancer       Date:  1978-11       Impact factor: 9.162

5.  Preclinical antitumor activity of a new Vinca alkaloid derivative, S 12363.

Authors:  A Pierré; L Kraus-Berthier; G Atassi; S Cros; M F Poupon; G Lavielle; M Berlion; J P Bizzari
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

6.  The protein binding of vinblastine in the serum of normal subjects and patients with Hodgkin's disease.

Authors:  W H Steele; D J King; H E Barber; G M Hawksworth; A A Dawson; J C Petrie
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Uptake of retinyl ester in HL-60 cells via the low-density-lipoprotein-receptor pathway.

Authors:  K O Wathne; B Carlander; K R Norum; R Blomhoff
Journal:  Biochem J       Date:  1989-01-01       Impact factor: 3.857

8.  Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy.

Authors:  S Vitols; B Angelin; S Ericsson; G Gahrton; G Juliusson; M Masquelier; C Paul; C Peterson; M Rudling; K Söderberg-Reid
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

9.  Binding of indapamide to serum proteins and erythrocytes.

Authors:  S Urien; P Riant; A Renouard; B Coulomb; I Rocher; J P Tillement
Journal:  Biochem Pharmacol       Date:  1988-08-01       Impact factor: 5.858

10.  Binding of vinca alkaloid analogues to human serum albumin and to alpha 1-acid glycoprotein.

Authors:  I Fitos; J Visy; M Simonyi
Journal:  Biochem Pharmacol       Date:  1991-02-01       Impact factor: 5.858

View more
  5 in total

1.  Nicanartine improves in vitro resistance of lipoproteins to oxidation.

Authors:  E Dailly; S Urien; P Wülfroth; J P Tillement
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

Review 2.  Mass balance studies, with a focus on anticancer drugs.

Authors:  Jan H Beumer; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients.

Authors:  Jing Li; Julie Brahmer; Wells Messersmith; Manuel Hidalgo; Sharyn D Baker
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

4.  The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum.

Authors:  B Cenni; J Meyer; R Brandt; B Betschart
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

5.  Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake.

Authors:  Robert Laplanche; Guy M L Meno-Tetang; Ryosei Kawai
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-03-13       Impact factor: 2.410

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.